The in vivo neuroprotective effect and brain levels of cis-4-phosphonomethyl-2-piperidine carboxylic acid (CGS 19755), a competitive N-methyl-D-aspartate (N MDA) antagonist, were compared with its in vitro neu roprotective effects. The dose-response for in vitro neu roprotection against both NMDA toxicity and combined oxygen-glucose deprivation (OGD) was determined in murine neocortical cultures. Primary cultures of neocor tical cells from fetal mice were injured by exposure to 500 fLM NMDA for 10 min or to OGD for 45 min. The effect of CGS 19755 in both injury paradigms was assessed mor phologically and quantitated by determination of lactate dehydrogenase release. Near complete neuroprotection was found at high doses of CGS 19755. The EDso for protection against NMDA toxicity was 25.4 fLmM, and against OGD the EDso was 15.2 fLM. For the in vivo Abbreviations used: BBB, blood-brain barrier; BSS 5.5, bal anced salt solution with 5.5 mM glucose; BSSO, BSS with no glucose; CGS 19755, cis-4-phosphonomethyl-2-piperidine car boxylic acid; D-APV , D-2-amino-5-phosphonovalerate; IND, ischemic neuronal damage; LDH, lactic dehydrogenase; MEM.
INTRODUCTION
The excitotoxic hypothesis (Rothman and Olney, 1986) , as a mechanism of damage following a cere bral ischemic insult, is supported by numerous find ings. Glutamate is postulated to be a main compo nent involved in neurotoxicity, acting in part through the N-methyl-D-aspartate (NMDA) recep tor (Goldberg et aI., 1987b; paradigm rabbits underwent 2 h of left internal carotid, anterior cerebral, and middle cerebral artery occlusion followed by 4 h reperfusion; Ischemic injury was assessed by magnetic reSonance imaging and histopathology. The rabbits were treated with 40 mg/kg i. v. CGS 19755 or saline 10 min after arterial occlusion. CSF and brain lev els of CGS 19755 were 12 fLM and 5 fLM, respectively, at 1 h, 6 fLM and 5 fLM at 2 h, and 13 fLM and 7 fLM at 4 h. These levels were neuroprotective in this model, reducing cortical ischemic edema by 48% and ischemic neuronal damage by 76%. These results suggest that a single i. v. dose penetrates the blood-brain barrier, attaining sus tained neuroprotective levels that are in the range for in vitro neuroprotection. Key Words: Ischemia Neurotoxicity-Glutamate-Blood flow-Evoked poten tials-Neuroprotection-NMDA. 1987). Both in vitro and in vivo data demonstrate that selective antagonists of this receptor provides neuroprotection against hypoxic-ischemic injury (Simon et aI., 1984; Gill et ai, 1987; Goldberg et aI., 1987a; Rothman and Olney, 1987; Kochhar et aI., 1988; Ozyurt et aI., 1988; Steinberg et aI., 1988 Steinberg et aI., , 1989a Steinberg et aI., ,b, 1991a .
Many studies showing neuroprotection against neurotoxicity have been carried out with non competitive NMDA antagonists such as MK-801, dextromethorphan, and dextrorphan (Gill et aI., 1987; Ozyurt et aI., 1988; Steinberg et aI., 1989a,b; Simon and Shiraishi, 1990; Steinberg et aI., 1991a,b) . Noncompetitive NMDA antagonists are extremely lipophilic and achieve high levels in the brain after systemic administration (Buchan, 1990; Steinberg et aI., 1991a) . Neuroprotection with these NMDA antagonists occurs only if they are admin istered before or up to 2 h after the onset of focal ischemia (Meldrum, 1990) .
Competitive NMDA antagonists have also been studied for their efficacy during ischemia. Although many competitive NMDA antagonists are hydro philic (Buchan, 1990) , and high brain levels can be obtained only with direct cerebral administration (Simon et aI., 1984) , newer competitive NMDA blockers provide neuroprotection when given sys temically. Among these, cis-4-phosphonomethyl-2piperidine carboxylic acid (CGS 19755; Selfotel) and D-(E)-2-amino-4 methyl-5-phosphono-3pentenoic acid appear to be efficacious during both global and focal ischemia (Grotta et aI., 1990; Tak izawa et aI., 1991; Warner et aI., 1991; Madden et aI., 1993; Sauer et aI., 1993) . For example, with global ischemia, CGS 19755 (30 mg/kg) adminis tered preischemia followed by four 25 mg/kg doses administered between 0.5 and 6.5 h postischemia markedly reduced striatal damage (Warner et aI., 1991) . Takizawa et ai. (1991) showed that CGS 19755 was neuroprotective in a focal ischemia model. CGS 19755 (30 mg/kg) provided significant neuroprotection if given at 5, but not 30, min after reversible spinal cord ischemia (Madden et aI., 1993) . CGS 19755 has also been found to be neuro protective in a global ischemia rat model (Grotta et aI., 1990) . However, the neuroprotective properties of CGS 19755 in vitro are not well characterized, as they have been for other NMDA antagonists (Gold berg et aI., 1987a; Goldberg and Choi, 1993) . Fur thermore, it is not known if CGS 19755 reaches neu roprotective levels in the brain with a single dose, particularly since this hydrophilic compound does not cross the blood-brain barrier (BBB) readily, and there is some question about the extent of brain uptake over time (Takizawa et aI., 1991; Hogan et aI., 1992) . CGS 19755 is currently being evaluated clinically in multicenter safety and efficacy trials for stroke (Grotta et aI., 1994) and head trauma.
In the present study, we determined the neuro protective levels and dose-response characteristics of CGS 19755 against NMDA toxicity and oxygen glucose deprivation (OGD), in vitro. While other investigators have demonstrated CGS 19755 neuro protection against in vivo ischemia with multiple drug doses, the current study was also designed to determine if a single postischemic dose of 40 mg/kg CGS 19755 would achieve in vitro neuroprotective levels, and afford protection against focal cerebral ischemia in our rabbit model. We measured CGS 19755 brain levels, which correlated well with con centrations required for in vitro neuroprotection against NMDA neurotoxicity and OGD. We report here excellent in vitro and in vivo neuroprotection with CGS 19755, against NMDA toxicity or OGD in culture and against focal cerebral ischemia.
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MATERIALS AND METHODS

Cell culture preparation
Dissociated mixed neocortical cultures containing both neurons and glia were prepared from fetal Swiss Webster mice at 14-16 days of gestation (Choi et aI., 1987) . The cells were plated at 2.5-3.5 hemispheres per 24-well cul ture dish (Falcon Primaria) on preexisting (prepared 2-6 weeks earlier) glial cultures made from neocortex of new born mice (PI-3). The cultures were plated in Eagle's Minimal Essential Medium (MEM; Earle's salts, supplied without glutamine) supplemented with 5% horse serum, 5% fetal bovine serum, 2 mM glutamine, and 21 mM glu cose. Cell cultures were fed twice weekly with the same medium, lacking fetal bovine serum. Cultures were kept at 37°C in a humidified incubator with a 5% carbon diox ide-in-air atmosphere and were used for experiments be tween 14 and 16 days in vitro.
In vitro injury paradigm
IO-min exposure to NMDA. Cell cultures were washed three times at room temperature by aspiration of the vol ume in each well to 125 .... . 1 and addition of 750 .... . 1 of balanced salt solution with the following composition (mM): NaCI 116, KCI 5.4, CaCI2 1.8, MgS04 . 7H20 0.8, NaH2P04· H20 1.01, and glucose 5.5; pH 7.4 (BSS5.5). This was followed by aspiration of the volume in each well to 125 .... . 1 and addition of 250 .... . 1 of the desired toxin or toxin/drug solution (500 .... . M NMDA, alone or + CGS 19755 at different concentrations ranging from I .... . m to I M). At the end of a 10 min exposure to the NMDA ± CGS 19755 solution, the cultures were washed three times (750 .... . Vwell) with MEM containing 2 mM glutamine and 5.5 mM glucose, and once more with 250 .... . Vwell of the same medium, to a final volume of approximately 375 .... . Vwell. Cultures were then returned to the incubator (3rC), and neuronal death was assessed 20-24 h later: first morpho logically, by phase-contrast microscopy and then quanti tatively, by determination of lactate dehydrogenase (LDH) release into the bathing medium (Koh and Choi, 1988) .
OGD. Cultures were washed three times in the anoxia chamber with a glucose-free salt solution with the follow ing composition (mM): NaCi 116, KCI 5.4, CaCI2 1.8, MgS04 . 7H20 0.8, NaH2P04 . H20 1.01 (BSSO) con taining 26 mM NaHC0 3 and bubbled with CO2 as previ ously described (Giffard et aI., 1990) . This was followed by the addition of 250 .... . 1 of BSSO, alone or with varying concentrations of CGS 19755. After 45 min of OGD, the cultures were washed three times (750 .... . Vwell) with oxy genated MEM containing 2 mM glutamine and 5.5 mM glucose, and a final time with 250 .... . Vwell of the same medium. Cultures were then returned to the normal cul ture incubator and neuronal death was assessed 20-24 hours later by phase-contrast microscopy and determina tion of LDH release.
The ED50 was calculated graphically as the CGS 19755 concentration required to prevent 50% of LDH release. The ED50 for both NMDA toxicity and OGD were calcu lated for each single experiment, and the mean was cal culated from all experiments in each condition.
Animal preparation for in vivo ischemia
New Zealand white male rabbits (2.5-3.5 kg) were se dated with I ml xylazine/acepromazine maleate (3: 1) and anesthetized with 3-4% halothane delivered by mask. Tracheostomy was performed; anesthesia was main-tained by mechanical ventilation with I % halothane in 0.5 Llmin O2: 4.5 L air. End-tidal CO2 was measured with a capnograph (Puritan-Bennett) and controlled at 30-40 mm Hg. Catheters were inserted into the right femoral vein and artery for blood pressure monitoring, blood sampling, and drug administration. MABP, rectal temperature, and heart rate were monitored continuously. MABP was maintained at 50-60 mm Hg throughout the clipping pe riod and at 60-70 mm Hg throughout the reperfusion pe riod, using small boluses of saline and neosynephrine (I ml in 50 ml saline) as needed. Cortical brain temperature was measured continuously with a 33 gauge thermocou ple (Omega) inserted into a hole drilled I cm lateral from the bregma, in the contralateral hemisphere, and lowered 4 mm into the brain. Brain temperature was controlled at 37.5-38.5°C with a heating lamp. Arterial blood gases (178 pH/blood gas analyzer; Ciba-Corning), plasma glucose levels (One Touch glucose monitor; Lifescan), and he matocrit were measured intermittently throughout the ex periment; metabolic acidosis was corrected with i. v. so dium bicarbonate as necessary.
Somatosensory evoked potentials
Median nerve somatosensory evoked potentials (SEPs) were recorded over both hemispheres with skull screws positioned 5 mm to either side of the sagittal suture at the bregma. Square wave stimuli (10 rnA and 0.25 ms dura tion) were delivered to the median nerves at a frequency of 2.1 Hz. SEPs were recorded and stored with the Nico let Pathfinder II Electrodiagnostic System. Thirty re sponses were averaged for each measurement with a band pass filter of 30-15oo Hz. The amplitude of the SEP wave was measured from the peak of the major positive deflec tion to the trough of the negative deflection (Steinberg et aI., 1986) . For purposes of analysis, SEP amplitudes were expressed as a percentage of preischemic amplitudes. In order to confirm consistent ischemia, we only used ani mals in this experiment whose SEP amplitude decreased to <25% of the preischemic values within the first 10 min after arterial occlusion. SEPs were recorded preischemia, at 15 min intervals during the 2 h ischemic period, and at 30 min intervals during reperfusion.
Cerebral blood flow measurements
A I mm diameter Laser-Doppler flow probe (TSI BPM 403 A) was placed over an � 2 mm diameter hole drilled in the skull (dura left intact), 10 mm to the left of the bregma. The probe was lowered with a micromanipulator and advanced, under microscopic guidance, to the sur face of the dura. Care was taken to not damage the brain while adjusting the probe position. Because the Laser Doppler method has been demonstrated to provide accu rate measurements of rCBF changes, but not of absolute flow (Dirnagl et aI., 1989) , all measurements were ex 'pressed as relative percentages of preischemic values.
Ischemic model
The model was modified from previous studies (Stein berg et aI., 1989a,b, 199Ia,b) . In the present study, using a retro-orbital approach, three vessels were occluded (left anterior cerebral artery, left internal carotid artery, left middle cerebral artery) with miniature temporary Yasargil clips (Steinberg et aI., 1991 a) . The three vessels were occluded for 2 h, followed by removal of the clips and 4 h of reperfusion. Ten minutes after the onset of arterial occlusion, rabbits were administered i. v. either 40 mg/kg CGS 19755 in saline (n = 8) or an equivalent vol ume of saline (n = 10), in a blinded fashion. Drug or saline was delivered over 10 min.
At 6 h after the onset of arterial occlusion, all animals were killed with an i.v. overdose of pentobarbital (100 mg/kg) and perfused transcardially with 300 ml saline fol lowed by 300 ml buffered formalin (pH 7.4). Brains were left in the skulls overnight, removed the next day, and allowed to sit in formalin for at least another 5 days before magnetic resonance imaging (MRI) scanning and histo logical processing.
Magnetic resonance imaging
MRI scans of the fixed brains were obtained with a 1.5 Tesla GE Signa Scan magnet with a 6 in diameter saddle coil positioned at the magnetic isocenter, a 16 cm field of view, a 256 x 256 matrix (0.625 mm pixel diameter), and 2 excitations/projections (17 min 10 s scan time). Three millimeter thick split echo T2 weighted images were ob tained with a repetition time of 2,500 msec and an echo time of 80 ms. We have previously shown a high corre lation (>85%) between in vivo MRI images and postmor tem images (DeLaPaz et aI., 1991) . High intensity re gions, representing ischemic edema, were measured with an image analyzing system (Jande! Sigma and IBM PC XT computer). Percentage area cortical edema for each ani mal was calculated as the sum of the left cortical areas of high intensity on four standard coronal images divided by the sum of the left cortical areas for those four images (Steinberg et aI., 1988, 199Ia) .
Histopathology
Histopathology was performed on paraffin embedded, coronal 10 fLm sections stained with hematoxylin and eosin. Five standard coronal sections were analyzed (Steinberg et aI., 1989a) . Areas containing neurons with early ischemic neuronal damage (IN D) were measured on each of the standard sections using an image analyzing system. IND was determined when neurons showed mod erate to severe shrinkage, increased nuclear basophilia, and pyknotic nuclei. Similar criteria have been used in previous studies (Ginsberg et aI., 1978; Tamura et aI., 1980; Steinberg et aI., 1988, 199Ia) . Percentage area of IND for each animal was calculated for the left cortex and striatum as the sum of the total area of IND for the left cortex or striatum divided by the total area of left cortex or striatum on five coronal sections.
CGS 19755 levels
In a procedure similar to the one described in the isch emia mode! section (see above), animals were divided into three groups: I h of ischemia and sacrifice (n = 5), 2 h of ischemia and sacrifice (n = 8), or 2 h of ischemia plus 2 h of reperfusion and sacrifice (n = 5). Ten minutes after occlusion, 100 fLCi of [ 3 H]CGS 19755 was added to a stock solution of 4 mg/ml CGS 19755. A 40 mg/kg bolus was administered via infusion pump over 5 min. Forty minutes prior to killing, 0.5 ml of a standard vial of so dium pyrophosphate was administered via ear vein to la bel red blood cells. Ten minutes prior to killing, Tc-99 m (1,000 fLCi, I ml) was administered via ear vein. A final blood sample was taken immediately before the animal was killed.
After the animal was killed with 100 mg/kg sodium pen tobarbital i. v., CSF was aspirated from the fourth ventri cle. Samples that appeared bloody or pink on gross in-spection were excluded. The brain was then immediately removed and dissected into regions of interest: left and right frontal cortex, temporal cortex, parietal cortex, cer ebellum, hippocampus, and thalamus/striatum. Brain, blood, and CSF samples were massed and placed into a gamma counter to determine Tc activity. After the tech netium was allowed to decay for at least 60 h, samples were solubilized with conventional liquid scintillation counting technique and placed in a beta counter for de termination of tritium activity. An internal standard was used for quench correction. The amount of CGS 19755 in the brain parenchyma was then determined by the follow ing equation (Sisson and Oldendorf, 1971) : eH activity in sample/ 3H activity in blood) -(Tc activity in samplel Tc activity in blood) = eH activity in brain parenchymal 3H activity in blood). This tracer method is acceptable, be cause CGS 19755 has been found to not be metabolized (Hogan et al., 1992) .
Statistical analysis
For the in vitro study, statistical analysis of LDH re lease was performed with ANOV A and unpaired Stu dent's t test. Kruskal-Wallis and Mann-Whitney tests were used to determine differences in CSF, blood and brain levels of CGS-19755, CBF, SEP, edema, and IND. Data are expressed as mean values ±SD; p values < 0.05 were considered significant.
RESULTS
In vitro neuroprotection
After a lO-min exposure to 500 j.LM NMDA >85% of the neurons appeared necrotic (i.e., with phase dark nuclei and loss of phase-light contours), while glial cells appeared normal, consistent with earlier reports (Choi et aI., 1987) . Addition of CGS 19755 resulted in a concentration-dependent reduction in neuronal death as assessed by phase-contrast mi croscopy and by measurement of LDH release into the bathing medium 20--24 h later. The mean (±SD) ED50 for CGS 19755 against NMDA toxicity was 25.4 ± 30.8 j.LM, determined from 6 experiments, each using 4 cultures per condition (Table 2) .
Forty-five minutes of OGD also resulted in loss of -85% of neurons, without glial degeneration (as re ported earlier, Giffard et aI., 1990) . Addition of CGS 19755 resulted in a concentration-dependent protection against OGD, according to cell morphol ogy and to amount of LDH release. The mean ED50 for CGS 19755 against 45 min of OGD was 15.2 ± 13.7 j.LM, determined from three experiments (four cultures for each condition in each experiment) (Ta ble 2). The mean ED50S for NMDA toxicity and OGD neuroprotection were not substantially differ ent from each other, in view of the standard devia tions.
In vivo neuroprotection
Blood, brain, and CSF levels. Blood levels of CGS 19755 increased very rapidly and declined J Cereb Blood Flow Me/ab, Vol. 15, No.5, 1995 over time. Brain and CSF levels also increased rap idly, but they remained high during the 4 h of study. Conversion of blood levels (j.LgJm!), CSF levels (j.LgJ ml) and brain levels (j.Lglg) to j.LM concentrations (assuming 1 g of brain = 1 m!) showed mean blood levels were 180.5 ± 74 j.LM at 1 h, 81.0 ± 49 j.LM at 2 h and 37.2 ± 37 j.LM at 4 h (Fig. 1) . As also illus trated in Fig. 1 , the mean CSF levels were 11.9 ± 7 j.LM at 1 h, 6.2 ± 2 j.LM at 2 h, and 12.7 ± 11 j.LM at 4 h. The mean brain levels were 5.0 ± 2 j.LM at 1 h, 5.1 ± 1 j.LM at 2 h, and 7.2 ± 4 j.LM at 4 h (Fig. O . The brain CGS 19755 levels at the time points mea sured were not statistically different from each other. The brain and CSF CGS 19755 levels reached were in the range of those found to be neuroprotec tive in vitro against NMDA toxicity and OGD.
Regional distribution of CGS 19755 in both the left and right hemispheres showed that CGS 19755 crossed the BBB in all six brain regions studied (Fig. 2) . In th e left hemisphere CGS 19755 levels ra n ged from 2.9 j.LM in the hippocampus to 17.9 j.LM in the frontal cortex. The left frontal cortex showed significantly higher drug levels than all other brain regions at all time points. Mean levels (±SD) in the ischemic left frontal cortex were 11.0 ± 3.6 j.LM at 1 h, 14.2 ± 6.7 j.LM at 2 h, and 17.9 ± 12.0 j.LM at 4 h. Mean levels of CGS 19755 in the right frontal cortex were 5.1 ± 2.3 j.LM at 1 h, 4.0 ± 1.4 j.LM at 2 h, and 8.4 ± 3.7 j.LM at 4 h; these levels were not signifi cantly different from those in the other right brain regions.
Systemic parameters. Physiological parameters during occlusion and 2 h after occlusion are shown in Table 1 . None of the parameters measured con tinuously during the experiment showed significant differences between groups, except pH in the CGS at 1,2, and 4 h after three-vessel arterial occlusion; a single dose of 40 mg/kg Lv. was given, 10 min after arterial occlu sion. Values are mean ± SD (brain and blood, n = 5, 8, and 5 for 1, 2, and 4 h, respectively; CSF, n = 5, 6, and 4 for corresponding time points). 19755-treated animals after occlusion; in this group, the mean pH was significantly lower (7.39) than it was in saline-treated controls (7.44). However, both pH values were within the normal physiological range.
Magnetic resonance imaging. CGS 19755 de creased overall cortical ischemic edema (sections 1-4) by 48% (saline controls: 48.6 ± 20.1% vs. CGS 19755: 25.1 ± 18.2%, p < 0.05). This neuroprotec tive effect was statistically significant at coronal levels 1 and 3 (p < 0.05), with a trend at level 2 (p = 0.06) (Fig. 3) . CGS 19755 was also effective in reducing hemi spheric edema. In sections 1-4, CGS 19755 de creased hemispheric edema by 54% (from 37.3 ± 19.0% in saline controls to 17.3 ± 16.0% in the CGS 19755 group, p < 0.05). Neuroprotection against hemispheric edema was found at coronal levels 1 and 2 (p < 0.05), with a trend at level 3 (p = 0.07).
Ischemic neuronal damage. Histological analysis
showed that CGS 19755 attenuated overall cortical IND (sections 1-5) by 76% (saline controls: 35.1 ± 10.7% vs. CGS 19755 group: 8.3 ± 3.5%, p < 0.001) (Fig. 4) . In sections 1, 2, and 3, CGS 19755 reduced cortical IND by 71, 75, and 83%, respectively (p < 0.001). In sections 4 and 5 . , CGS 19755 decreased cortical IND by 74 and 79%, respectively (p < 0.01).
Similar reductions in percent hemispheric IND by CGS 19755 were observed in all coronal sec tions. CGS 19755 reduced percent hemispheric IND by 70, 76, 69, 81, and 89% in sections 1, 2, and 3 (p < 0.001), and 4 and 5 (p < 0.01), respectively.
No significant neuroprotection by CGS 19755 was found in the basal ganglia (p = 0.143). IND in basal ganglia was 71.5 ± 34.9% in saline group ver sus 47.6 ± 34.1 % in CGS 19755 group. When basal ganglia was separated into putamen and caudate, a significant neuroprotective effect was still not ob served.
Cerebral blood flow. Measurements of CBF in the left hemisphere (hemisphere undergoing focal ischemia) are shown in Fig. 5 . In the CGS 19755 group, the mean CBF dropped to 11.4 ± 3.2% of preischemic values (p < 0.01; n = 8), and in the saline group, the mean CBF dropped to 9.6 ± 3.2% of preischemic values (p < 0.01; n = 10). No sta tistical difference in CBF was found between the two treatment groups at any time during the exper iment.
Somatosensory evoked potentials. SEPs in the left hemisphere during ischemia and during the reperfusion phase are shown in Fig. 6A . Although no significant difference was found between the two groups, a trend was observed, the CGS 19755 group having lower amplitudes than those in the saline group. SEPs recovered to 75.6 ± 70.4% of the preis chemic values in the saline group, and to 35.2 ± 18.7%, in the CGS 19755 group.
In the right hemisphere, where no ischemia was induced, CGS 19755 significantly reduced the SEP amplitudes compared with those of control animals (Fi g . 68). In the CGS 19755 group, there was a 67% fall in SEP amplitUde from preischemia until the onset of reperfusion, and in the saline group , there was a l2% decrease during the same time period. In the saline group. SEP amplitude at the onset of reperfusion was 88.4 ± 49.0% of preischemia val ues, and in the CGS 19755 group, it was 33.1 ± ]5.5% (p < 0.05).·A significant difference in SEP amplitude between the two groups was also ob served during the first 2 h of reperfusion (hours 2-4 following ischemia} (Fig. 68 ).
DISCUSSION
The results from the present study utilize two dif ferent paradigms (in vitro and in vivo) to determine J Cereb Blood Flow Metab. Vol. 15. iVo. 5, fQ95 the neuroprotective properties of the competttlve NMDA antagonist. CGS 19755, against focal isch emia. This approach is helpful both in elucidatin g possible mechanisms of action and in determining the levels required for CGS 19755 protection against focal ischemia.
In vitro ischemia
The good correlation between in vitro and in vivo neuroprotective levels found in the present study supports the contention that experiments in cell cul ture may aid in determining an approximate concen tration for neuroprotection in vivo. Nonetheless, ex trapolating from tissue culture to in vivo experiments cannot be assumed, and neuroprotective efficacy must be determined for specific injury paradigms. In our cell culture injury paradigm, CGS 19755 was administered at the onset of either NMOA tox icity or aGO and reached the cells immediately. As observed by Goldberg and Choi (1993 , 1989) , and OGD (Goldberg and Choi. 1993) . Many of these studies have used noncompetitive NMDA antagonists (Hartley and Choi. 1989; Choi, 1990. 1993) . Fewer studies have examined protection against excitotoxicity with competitive NMOA an tagonists. The competitive effectiveness of NMDA blockers depends on the level of glutamate release: thus, the greater the concentration of excitatory amino acids released. the greater the concentration of competitive antagonist that may be required, as seen in studies with D-2-amino-5-phosphonovaler ate (D-APY) (Goldberg et aI., 1987b; Goldberg and Choi, t993) . Previously. CGS 19755 was shown to be neuroprotective against OGO at 100 j.l.M (Gold berg and Choi. 1993) , but a dose response curve was not determined. The present study found an EDso of 25.4 J-lM against NMOA excitotoxicity and 15.9 fLM against 45 min of OGD. These values were in the same range as those necessary for neuropro tection, given the variability between experiments. In vivo ischemia Levels of CGS 19755. The present study demon strates that CGS 19755 readily crosses the BBB. Neuroprotective levels of CGS 19755 were achieved in CSF and brain after a single dose of CGS 19755 (40 mg/kg) 10 min after occlusion. In contrast with the rapid clearance of CGS 19755 found in plasma, levels in CSF and brain remained high for at least several hours, which suggests that continued maintenance dosing of CGS 19755 is not required to sustain high brain levels for up to 4 h. In the present study CGS 19755 reached the brain very rapidly, contrary to a previous study that � CGS-19755 _ Saline Ooronal level showed very slow uptake into the rat brain (Hogan et aI., 1992) . Hogan et al. (1992) indicated that the average brain uptake in regions supplied by the mid dle cerebral artery was 0.15% (index of CGS 19755 relative to iodoantipyrine). The regional plasma clearance these investigators observed across the BBB during normoxia averaged only 0.015 100 g-l min -I; during ischemia it was 0.019 in the ischemic hemisphere and 0.009 in the non-ischemic hemi sphere. No significant regional differences in plasma clearance of CGS 19755 were observed in either normal or ischemic rats except in the cortex injured by electrocautery, where a 14-fold increase in clearance across the BBB was measured (Hogan et aI., 1992) . This may be an additional explanation for the higher levels found in our experiment within the cortical area closest to the enucleation site. The different results reported by Hogan et ai. (1992) compared with our results in the present study may be due to differences in species or ischemic models. However, the rapid anesthetic effect of CGS 19755 showed by Daniell (1991) in mice suggests that, de spite the apparently slow uptake of CGS 19755, it reaches levels with physiological effects very rap idly, as indicated by the results of our present study.
Interestingly, we also found that levels in the ischemic left frontal cortex were higher than in the contralateral counterpart. This effect may be ex plained by changes in the BBB due to ischemia. For example, Anwar et ai. (1993) showed that 1 h of middle cerebral artery occlusion in rats increased capillary permeability to small molecules more than 4-fold in the ischemic cortex. Also, Preston et ai. (1993) demonstrated transfer constants for blood to brain permeation of eH]sucrose were augmented several fold in forebrain ischemia, indicating wide spread opening of the BBB. Hogan et ai. (1992) re ported that plasma clearance across the BBB of CGS 19755 was similar to that found for sucrose during ischemia. Preston et ai. (1993) also showed a delayed intensification of opening in the striatum and hippocampus, regions that undergo selective, delayed neuronal cell death. Possible mechanisms for this early opening of the BBB include arachi donic acid and eicosanoids, bradykinin, histamine, and free radical formation. These active compounds may increase cytosolic calcium levels and induce second messenger systems leading to BBB alter ations (Greenwood, 1991) .
Neuroprotection during in vivo ischemia. The present study showed excellent neuroprotection by CGS 19755 against cortical ischemic neuronal dam age (76% decrease) and ischemic edema (48% de crease in cortical edema; 54% decrease in hemi spheric edema). Although this was not a dose response study, the robust neuroprotective effect, compared with the effects of other neuroprotective agents (CGP 40116, dextrorphan, dextromethor phan, MK-801, dexmedetomidine) we have previ ously examined (Steinberg et aI., 1989a (Steinberg et aI., ,b, 1991a Maier et ai. 1993) , suggests that 40 mg/kg of CGS 19755 may have provided maximal protection. It is likely that lower doses of CGS 19755 (achieving lower brain and CSF levels) would also provide some neuroprotection. Similar neuroprotection has been obtained in dif ferent models of ischemia and in different species. With global cerebral ischemia in gerbils Boast et ai. (1988) found that repeated doses of CGS 19755 re duced ischemia-induced hippocampal brain dam age. Warner et ai. (1991) demonstrated that admin istration of CGS 19755 (30 mg/kg) either before or 5 min after occlusion, followed by administration of four additional doses, protected the striatum against ischemic damage. Quinolinic acid-induced degener ation of striatal cholinergic and GABAergic neurons is also blocked by CGS 19755 (Massieu et aI., 1993) . Neuroprotective efficacy of CGS 19755 was also found in the rat following permanent middle cere bral artery occlusion (Sauer et aI., 1993) , 1991) and mouse (Gotti et aI., 1990) . Delayed ther apy of CGS 19755 was evaluated in a reversible spinal cord ischemia model in rabbits: CGS 19755 (30 mg/kg) showed significant efficacy if given at 5 min after the onset of ischemia, but not if given 30 or 60 min afterwards (Madden et aI., 1993) . CGS 19755 failed to significantly attenuate isch emic neuronal damage in the striatum. This is con-Time (h) sistent with our previous work showing lack of ben efit in that region from other neuroprotective drugs (CGP 40116, dextrorphan, dextromethorphan, MK-801, dexmedetomidine: Steinberg et aI., 1989a ,b, 1991a Maier et aI., 1993) , and it may relate either to a lack of a collateral blood supply or to a less im portant role of NMDA-mediated excitotoxic injury in the striatum.
One limitation of the present study is the rela tively short perfusion period (4 hours), so that out-
come is determined at 6 h after onset of ischemia. While the histological criteria we employed fo r early ischemic neuronal injury (shrunken. angular basophilic neurons with dark-staining nuclei) are suggestive of cerebral infarction (Brierley . 1973; Garcia and Kamijyo. 1974; Little et aI . , 1974; Gins berg et aI ., 1979 ; Tamura et aI., 1980) , delayed neu ronal damage may progre ss fo r days in the case of global ische mia and up to at least 12 h under certain conditions of fo cal ischemia (Pulsinelli et aI ., 1982 ; Dereski et aI ., 1993 ; Dietrich et ai ., 1993) . It is pos sible that CGS 19755 merely delays the course of ischemic neuronal death but does not alter the final outcome at a later time point. However, other groups have demonstrated CGS 19755 neuroprotec tion against ischemic injury after 72 h (Grotta et aI ., 1990; Simon and Shiarishi , 1990) and 96 h (Boast et aI ., 1988) .
Putative mechanisms fo r neuroprotection . CGS 19755 may protect against ischemic cerebral injury by blocking NMDA-induced toxicity, th us prevent ing a subsequent cascade of detrimental event s (Siesjo , 1981) . CGS 19755 inhibits NMDA-evoked ·depolarizations (Bennett et al .. 1989 (Bennett et al .. , 1990 . par tially inhibits glycine binding to the NMDA recep tor (Grimwood et aI., 1993) , and attenuates extra cellular glutamate release posttraumatically (Panter and Faden, 1992) . CGS 19755 also reduces Ca 2 • entry into ne urons (Grotta et aI ., 1990) , attenuat es postische mic cere b ral glucose hypermetabolism (Simon and Shiarishi, 1990) , and improves cerebral pH after fo cal ischemia (Takizawa et aL. 1991), It is unclear why the noncompetitive NMDA an tagonist dextromethorphan increases the SEP am� plitude in the nonischemic and ischemic hemi spheres (Steinberg et aI ., 1988) . while CGS 19755 reduces the SEP amplitude. However. the variable eIectrophysiological re sponses may relate to the sites of action of these drugs on the NMDA recep tor or to effects at other sites (Sagratella et aI ., 1991) . For instance, dextromethorphan interacts with distinct dextromethorphan receptors . voltage dependent Ca2 1c hannel receptors (Carpenter et aI., 1988) , and tbe sigma opi oid site as well as with noncompetitive. NMDA sites (Tortel1a et al.. 1989b) . Additionally, these different NMDA antag onists may preferentially block certain subpopula tions of NMDA receptors that have different effects on SEPs . It is al so possible that CGS 19755 blocks NMDA receptors at some point on the affe re nt pathway.
Results of other studies have suggested that NMDA antagonists may protect by improving col lateral perfusion during and aft er ischemia (Tortella et aI., 1989a ; Steinberg et a\ ., 1991b; Lo and Stein-J Cer�b Blond Flo,,' Merab. Vol. IS . No 5. 1995 berg, 1991; Buchan et al . . 1992) . However, in the present study we did not observe a change in CBF fo llowing CGS 19755 treatment (see Fig. 5 ). This discrepancy may be due to differences between spe cies, ischemic models, anesthetic agents, or other fa ctors . Although blood pH after occlusion was slightly lower in the CGS 19755 group than in the control group (7 .39 vs. 7.44) , we doubt that this could explain the neuroprotective effect, since both pH values were within the normal physiological range .
In conclusion , we re port here that administration of CGS 19755 at a single i. v. dose of 40 mg/kg readily penetrates the BBB, reaching levels at 4 h in the ischemic brain (7 .2 ,.., M) and CSF (12.7 ,.., M) that fal l within the range fo und fo r in vitro neuroprotec tion fro m NMDA toxicity (ED50 of 25.4 f.l.M) and OGD (ED so of 15.2 ,.., M). This dose was sufficient to achieve neuroprotective levels in the brain: it was efficacious against a focal ischemic insult of 2 hand 4 h of re perfusion , decreasing both edema and neu ronal damage . However. CGS 19755 efficac y agai nst delayed neuronal damage remains to be de termined in this model . We suggest that the neuro protection observed in this model may reflect pri maril y neuronal protection at the cellular level , rather than improved collateral blood flow or pro tection through systemic effects . 
